Thyroid eye disease
Drug research and approvals for thyroid eye disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 70 studies of thyroid eye disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 16 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 70
- Trials authorized in Canada: 16
- FDA orphan approvals: 1
- EU medicines: 1
- Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye DiseaseNCT07885605 · Phase 1 · Ethyreal Bio, Inc. · starts Jul 6, 2026
- Comparative Evaluation of 68Ga-FAPI and 68Ga-DOTATATE PET/CT and PET/MRI in Thyroid Eye DiseaseNCT07835607 · Not reported · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · starts Nov 14, 2025
- An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to TeprotumumabNCT07832136 · Phase 4 · Viridian Therapeutics, Inc. · starts Oct 19, 2026
- Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' DiseaseNCT07812194 · Not reported · University of Copenhagen · starts Oct 16, 2026
- Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)NCT07753603 · Phase 3 · Sling Therapeutics, Inc. · starts Aug 4, 2026
- A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease…NCT07722546 · Phase 2 · Biogen · starts Jul 30, 2026
- Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE…NCT07716397 · Not reported · Shanghai Changzheng Hospital · starts Jan 1, 2026
- Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' DiseaseNCT07682896 · Phase 2 · Yarrow Bioscience, Inc. · starts Jun 10, 2026
- Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' DiseaseNCT07661056 · Phase 3 · Biohaven Therapeutics Ltd. · starts Jun 26, 2026
How its trials ended
149 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 25 whose ending is known, 32% met their primary endpoint, 4% missed it and 64% stopped early.
- Ongoing5436%
- Completed, result not reported4329%
- Status unknown2718%
- Stopped: other or unclear96%
- Met its primary endpoint85%
- Stopped: sponsor or business decision32%
- Stopped: lack of efficacy21%
- Stopped: enrollment or feasibility21%
- Missed its primary endpoint11%
| Oct 30, 2026 | An open-label, rollover study for participants with thyroid eye disease previously enrolled in amgen-sponsored amg 732 studies and are primary proptosis…Amg 732 | Amgen | Pending |
| Sep 14, 2026 | A phase 3, randomized, double-mask, placebo-controlled study with open-label extension to evaluate the efficacy and safety of linsitinib in participants with…Linsitinib (VGN-001, ASP7487, OSI-906AA) | Sling Therapeutics Inc | Pending |
| Aug 18, 2026 | A phase 2a open-label, proof of concept trial to evaluate the efficacy and safety of inebilizumab in participants with active thyroid eye disease (TED)Uplizna | Amgen | Pending |
| Sep 5, 2025 | A phase 1/2, randomized, double-masked, placebo-controlled, multicenter study to assess the safety, pharmacokinetics, and efficacy of amg 732 in healthy…Amg 732 | Amgen | Ongoing |
| Feb 25, 2025 | A phase 3, randomized, double-masked, placebo-controlled, multicenter study to evaluate the eficacy, safety, tolerability, pharmacokinetics, pharmacodynamics,…Efgartigimod PH20 (ARGX-113) | argenx US | Ongoing |
| Jun 26, 2024 | A phase 3, randomized, double-masked, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy, safety and tolerability of subcutaneous…Teprotumumab | Amgen | Ongoing |
| Oct 26, 2023 | A multicenter phase 2b randomized, double-masked, placebo-controlled dose-ranging study of TOUR006 in participants with thyroid eye diseaseTOUR006 | Tourmaline Bio | Ongoing |
| Oct 6, 2023 | An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal studiesVRDN-001 | Viridian Therapeutics | Pending |
| Sep 29, 2023 | A randomized, double-masked, placebo-controlled safety, tolerability, and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the…VRDN-001 | Viridian Therapeutics | Pending |
| Jul 18, 2023 | A phase III, randomized, double-masked, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of…Enspryng | Roche | Closed |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jan 21, 2020 | TeprotumumabTEPEZZA is indicated for the treatment of Thyroid Eye Disease. | Horizon Therapeutics Ireland DAC | Approved |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jun 19, 2025 | TepezzaTeprotumumab | Amgen Europe B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA